Collection power blast shed! It is expected that the total savings of 12.4 billion yuan and 45 varieties in one year will be 55 billion yuan

There are 118 enterprises to be selected, 158 products to be selected, with an average price reduction of 52%, a maximum decrease of 96%, and the proportion of enterprises to be selected has been raised to 71%.
the fourth batch of fast-track battle, the official list of candidates has been announced on the evening of the 3rd.
estimates, the fourth batch of drug collection is expected to save 12.4 billion yuan in one year.
, the total sales of 45 varieties in China's public medical institutions terminal reached 55 billion yuan is about to change.
this is the first large-scale injection collection at the national level since May 14, 2020, when China started the evaluation of the quality and efficacy of chemical injection generics.
, an official close to the health-care bureau, said, "The eight injections included in the collection fell by an average of 75 percent."
proton pump inhibitors, such as anti-tyrazole injections, are typical of gold sales, and there is a serious phenomenon of false height.
, through the collection of squeeze in the middle of the medical industry and gray areas, has contributed to a substantial reduction in product prices, so that patients really benefit, is the fundamental purpose.
" How will the winning company quote if the maximum price has been set and the purchase volume is known? Why can foreign investors offer the lowest winning bid? 01 Colum rushed out of the group of death, "the price is better" as the largest point of view of this collection, the collection of 45 varieties although only 8 injection forms, but accounted for 31% of the total amount of drugs purchased.
2019 public hospital terminal sales of five of the eight varieties exceeded 1 billion yuan, and two varieties had sales of more than 5 billion yuan.
of the National Drug Joint Procurement Office, the average price reduction of the injection was 75%.
17 and 14 enterprises were involved in the two death groups of Parexib injections and ammonia bromoso injections.
because the patient's access to the injection is far less than the oral preparation, once the product is not evaluated or the collection failed to win the bid, the impact on the enterprise can be imagined.
for companies that have won the bid for injections, it's still worth celebrating for them to be able to bid at a better price, even if they're going to have to cut prices in exchange for market usage.
For example, China's leading large infusion enterprises, Colum Pharmaceuticals, yesterday has posted a happy news, announced that its four products 6 specifications all selected the fourth batch of national drug centralized procurement, including 3 injection products, respectively, Parrxib injection (20mg/40mg), propofol medium / long chain fat emulsion (20ml: 0.2g), amin bromide injection (2 ml15mg).
Colum in two so-called "groups of death" in the collection of varieties, successfully winning the bid, a company official said that "the winning bid price is also ideal."
According to the Shanghai Sunshine Procurement Network announced the results of the proposed winning results, a total of 10 enterprises to choose the Parexib injection, the winning bid price of 2-6 yuan / bottle range, Emeishan Tonghui pharmaceutical price is the lowest, 2.98 yuan.
Colum for the variety of domestic first imitation, in November 2020 only through the consistency evaluation, Colum 40mg quoted 5.64 yuan, with the 9th line of pressure selected, the supply area for Hunan, Ningxia, Xinjiang (including the corps).
, according to the Koren announcement, its proposed winning bid for Parrestib injections (20mg plus 40mg) will have sales revenue of RMB519.5 million in 2019 and RMB497.81 million in 2020.
in this collection, Colum Pharmaceuticals' proposed winning injection of propofol/long-chain fat emulsion was approved in 2020, and Curran Pharmaceuticals won the bid with a maximum price of 14.858 yuan.
can quickly open up the market after winning the bid, its supply area is Jiangxi, Hubei, Guangdong, Hainan, Chongqing, Yunnan, Shaanxi.
ammonia bromine injections are also 10 enterprises to be selected, each winning bid price of less than 1 yuan, Yunnan Longhai offer the lowest, each only 2 cents, Shi four drug prices fell by up to 96%.
(2ml:15mg) only announced in early January this year that the product passed a consistent evaluation, the collection price of 0.338 yuan, the supply area for Jilin, Henan, Chongqing.
2020, a total of 15 varieties of Colum Pharmaceuticals were approved, 11 injections were evaluated and 2 innovative drugs were approved clinically, according to Milnenet data.
there are currently 36 varieties of Columbo (16 of which are the first), 13 of which are injectables.
At the beginning of this year, in addition to the consistent evaluation of ammonia bromosot injections, Colum Pharmaceuticals also has a number of products such as fat milk (10%)/amino acids (15)/glucose (20%)injections, sodium fluconazole chloride injections, hydrochloric acid right metomycin injections, medium/long chain fat emulsions (C8 to 24Ve) that have passed consistent evaluations.
02 injection varieties are changing days after the baptism, injection market "change days" is difficult to avoid.
Volume price linkage" does not mean that enterprises can simply consider low-cost winning bid, capacity, cost and loss degree are also in the enterprise's quotation strategy, the fourth batch of collection, the original research lowest price winning bid, dark horse enterprises kill the heavy siege, but the price is not the lowest enterprises to get a higher market share of the case emerge endlessly, the enterprise's quotation strategy is what? "Up to ten companies may be allowed to bid", a rule that appears to be for ammonia bromoso injections and Parexib injections.
They also without exception become the most interesting varieties of this collection, each has 16 evaluation enterprises and the original research and drug companies to compete for 10 tickets to collect, the competition can be described as unusually fierce, so the emergence of floor prices is not surprising.
of the eight injectable varieties adopted in this collection, the amin bromine injection is the second largest injection variety after the sodium pentoladone injection.
aminine bromosot injections are mainly used to treat respiratory diseases, although in recent years, public medical institutions end-of-the-point ammonia bromosoin injection sales showed a downward trend year by year, but in 2019 there is still nearly 6 billion yuan market size, reaching 5.98 billion yuan.
In addition to the original research Blinger Ingeham, the domestic has Beenn, Qilu, Osaikang, Haizheng, Tianqing, Hengrui, Yangzijiang, Pro, Yuandong, Cylon, Tonghui, Luoxin, Sanhe, Tongde, Connbey, Baiyu and other nearly 20 production of ammonia bromide injections, has been evaluated up to sixteen enterprises.
with the original research BI in the collection of early exit, before the original research occupies more than 20% of the market share situation or will no longer exist.
, Yunnan Longhai won the lowest winning bid at a price of 0.23 yuan.
the top price of the ten enterprises selected in the election is only 0.66 yuan, a veritable floor price.
in terms of the winning bid and procurement volume of the ten bid companies in the ammonia bromo-sox injection, not the lowest winning companies benefit the most.
Yunnan Longhai, although the lowest price in this round, so get the advantage of the position, but perhaps due to factors such as production capacity, its procurement volume is only 1946.8201 million units, ranking fourth among ten enterprises.
If calculated according to the market share of the winning bid price of 80% of the first year of the winning province procurement volume, Yunnan Longhai only accounted for about 6% of the collection market share, becoming the lowest of the same product regulations.
But even so, this ratio is more than its 3.61% market share in 2019, while Jiangsu Hai'an Pharmaceuticals is expected to gain 15% of the market share with the highest winning bid of 0.66 yuan.
for enterprises such as Jiangsu Hai'an, which have a lower market share before mining, a successful bid will help to increase their market share and achieve corner oversized vehicles.
hai'an, Jiangsu Province, or will become the "winner" in the collection of ammonia bromosot injections.
this service, the sales pattern of ammonia bromotide injections in China is bound to change.
the same as the ammonia bromoso injections in the death group, the contestants were also face-to-face.
Parexib is a selective cyclooxidase-2 inhibitor, mainly used in the treatment of postoperative pain, is one of the basic drugs for clinical multi-mode analgesia.
Injection with Parexib sodium can be injected intravenously, but also intramuscular injection, can effectively meet the postoperative analgesic needs of rapid effectiveness and patients can not eat clinical needs, widely used in general surgery, gynecology, orthopaedics, orthopaedics and other departments of postoperative pain treatment.
In addition to the original pharmaceutical company Pfizer, the drug 40mg product evaluation enterprises, Qilu, Luo xin, Haizheng, Yuandong, Osaikang and other well-known pharmaceutical companies are in its list.
of public hospital terminals in 2019 was 1,994 million yuan, up 54.7% YoY.
, Pfizer and Colum dominate the current market share of Parexib injections, which account for 26% of the drug's sales of $519 million.
"Parexib injection may be less than 3 yuan" set before a guess even be used.
2.98 yuan, on January 20, just through the consistent evaluation of Emeishan Tonghui won the first bid, with the lowest price to win the Zhejiang, Henan, Guangxi, Chongqing market.
, which previously had a large market share in the breed, finished in ninth place, with an expected share of about 6%.
, as Colum Pharmaceuticals has publicly stated, regardless of the outcome of the winning bid, prices will be affected and the chosen area will be compressed.
static analysis, generally speaking, the market share of more than 50%, sales of more than 100 million yuan of varieties if not winning the bid, the loss of enterprises is larger, in this case, in this variety of enterprises are "aspirational", that is, by significantly reducing the floor price to obtain tickets to the market.
such a variety as propofol medium/long-chain fat emulsion.
meters of intranet data show that in the first half of 2020, China's public medical institutions terminal propofol / long-chain fat emulsion sales of 1.9 billion yuan, of which Fessenyuscabi market share of 61.92 percent, sales of more than 700 million yuan.
it is worth noting that in this collection, Fessenyuscabi is also a "blood book", throwing 9.86 yuan / branch, 85% lower than the maximum price of the offer to win the preference.
E drug managers according to the collection of official documents calculated that Fessenyuscabi will be selected in Beijing, Shanxi, Inner Mongolia, Liaoning, Shanghai, Zhejiang, Fujian, Guangxi, Ningxia to get 3.59032 million units of procurement volume, the first year is expected to sales of about 35.4006 million yuan, in the winning enterprise ranked second, but due to the advantages of the original research, the market share outside the collection of 20% of the hospital may also be in the competition.
In addition to Fessen Yuscabi, propofol/long-chain fat milk injections were also awarded by Yangzijiang, Jiangsu Yingke and Koren, with quotations of 12.5 yuan, 13.4 yuan and 14.854 yuan, respectively, and were approved in categories 4 after October 2020 and evaluated as consistent.
It can be seen that these three enterprises have not achieved sales before, propofol in these enterprises did not occupy a larger share of the performance, and the price reduction of 80% to bring more than 30 million yuan in sales, with market share of more than 50%, annual sales of nearly 2 billion yuan of Fessenyuscabi can be said to be "lying win."
And the four medium-sized enterprises will get the market sum, propofol medium / long chain fat emulsion 80% of the market total market total of about 138 million yuan, and the market before the collection of nearly 4 billion yuan in annual sales.
's other market for varieties entering the collection has declined even more significantly, with Mienet data showing that the end-user sales of pythonazole injections in domestic public hospitals in 2019 amounted to 6.669 billion yuan, the largest of the eight collected injections.
this collection, 80% of the market share of the variety will shrink to 140 million yuan.
this variety also shows the characteristics of the state-level "quantity price linkage", the lowest price of the winning bid in east China and the United States to get the largest market, annual sales are expected to reach 3.638 million yuan.
that the winning bid price in East China was 2.56 yuan per branch, a decrease of about 91% from the maximum price.
The market share of the other five target enterprises is relatively average, it is worth noting that the highest price of 4.94 yuan / branch of the winning bid, will be divided into 18.4115 million yuan of the market, and Chengdu Tongde Pharmaceuticals with the fourth-place price of 2.84 yuan / branch, the market share of only 16.8879 million yuan.